Biotricity Inc (OTCPK:BTCY)

Q2 2025 Biotricity Inc Earnings Call Transcript

Nov 15, 2024 / 09:30 PM GMT

Release Date Price: $0.4505 (+12.63%)

Transcript 8-K10-Q

Key Points

Positve

Biotricity Inc (BTCY) achieved positive EBITDA for the first time in September, marking a significant milestone towards profitability.
The company reported a 13% year-over-year increase in revenue for Q2 2025, reaching $3.3 million, driven by strong demand for their cardiac monitoring devices.
Biotricity Inc (BTCY) has successfully transitioned approximately three-quarters of its business to a flat fee subscription model, resulting in a 34% year-over-year growth in flat fee revenue.
Strategic partnerships with top group purchasing organizations (GPOs) and specialist organizations in neurology and pulmonology are expanding market reach and creating new opportunities.
The company has improved its gross profit margin to 75.3%, up from 73.8% in the prior year, due to efficiencies gained through proprietary AI and operational improvements.

Negative

Despite improvements, Biotricity Inc (BTCY) still reported a net loss of $1.65 million for Q2 2025, although this is a reduction from the previous year.
The company faces challenges with longer sales cycles, particularly in larger clinics and hospitals, which could delay revenue realization.
Operating expenses remain high, although they have decreased by 34% compared to the same period last year.
Biotricity Inc (BTCY) is still in the early stages of its partnerships in neurology and pulmonology, making it difficult to predict the full potential of these markets.
The company is reliant on its inventory order to achieve profitability, indicating potential risks if sales targets are not met.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BTCY.PK - Biotricity Inc
Q2 2025 Biotricity Inc Earnings Call
Nov 15, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the bio conference call at this time. All participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded.

It is now my pleasure to introduce founder and CEO Doctor Wakas Al Sadiq. Thank you. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you everybody for joining us today. Second quarter, 2025 has been a transformative quarter for biotricity marked by

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.